Effect of an IRF3 inhibitor on ovarian cancer cells
Abstract
In these studies, we investigated the effect of phenylmethimazole (C10), an IRF3 inhibitor, on the proliferative capability of ovarian cancer cells, and on their behavior in wound healing assays. In addition, we investigated the expression of inhibitor molecules CD47 and PDL1 on these cells. Although the treatment was not able to significantly affect proliferation, we observed a decrease in the capability of these cells to timely close the gaps generated in the context of wound healing assays. Further studies will investigate the overall response of these cells to phenylmethimazole to evaluate its anticancer potential for ovarian cancer.
Status
Graduate
Department
Chemical and Biomolecular Engineering
College
Russ College of Engineering and Technology
Campus
Athens
Faculty Mentor
Benencia , Fabian
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Effect of an IRF3 inhibitor on ovarian cancer cells
In these studies, we investigated the effect of phenylmethimazole (C10), an IRF3 inhibitor, on the proliferative capability of ovarian cancer cells, and on their behavior in wound healing assays. In addition, we investigated the expression of inhibitor molecules CD47 and PDL1 on these cells. Although the treatment was not able to significantly affect proliferation, we observed a decrease in the capability of these cells to timely close the gaps generated in the context of wound healing assays. Further studies will investigate the overall response of these cells to phenylmethimazole to evaluate its anticancer potential for ovarian cancer.